IBB Stock Recent News
IBB LATEST HEADLINES
Over the weekend as we looked at the entire Economic Modern Family of stock market ETFs, we focused on Big Brother Biotechnology IBB as particularly intriguing. We wrote: “IBB sits just below the 200-WMA.
The iShares Biotechnology ETF (IBB) was launched on 02/05/2001, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on 02/05/2001.
Innovation has been a hallmark of biotechnology for decades and, despite some of the hardest sledding in many years, 2024 could be a bounce-back year for biotech stocks. The sector has suffered in this cycle.
Weight loss has long been a challenge for many people, me included. Indeed, there are an estimated 1 billion individuals living with obesity, and the Obesity World Atlas estimates this could rise to 1.9 billion by 2035.
The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the sector has enjoyed a significant rally after bouncing off its uptrend support and now consolidating near several major Simple Moving Averages (SMA).
Wall Street was in great shape on Monday, with the S&P 500 experiencing its largest three-day rally of the year.
Watching certain instruments for clues on next moves, probably the best (equities) to watch is the Economic Modern Family of stock market ETFs. These ETFs cover everything from tech to regional bank stocks to small cap stocks to retail stocks and more.
A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market.
Biotech's next gold rush is weight-loss drugs. There is a dominance of NVO and LLY in this space for now, notes Rahul Jasuja.